Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Santen Pharmaceutical Co ( (JP:4536) ) just unveiled an update.
Santen Pharmaceutical Co., Ltd. announced the status of its share buyback program, having repurchased 5,236,000 common shares for a total of 8,248,657,100 yen between August 1 and August 31, 2025. This buyback is part of a larger plan approved by the Board of Directors to repurchase up to 19,800,000 shares, representing 5.8% of the total outstanding shares, with a maximum budget of 35 billion yen, aimed at enhancing shareholder value and optimizing capital structure.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen2600.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals worldwide. With over 130 years of experience, Santen focuses on the research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries.
YTD Price Performance: -2.18%
Average Trading Volume: 1,386,014
Technical Sentiment Signal: Buy
Current Market Cap: Yen533.8B
For an in-depth examination of 4536 stock, go to TipRanks’ Overview page.